Loss of LZAP Inactivates P53 and Regulates Sensitivity of Cells to DNA Damage in a P53-dependent Manner

Overview

Journal Oncogenesis

Date 2017 Apr 11

PMID 28394357

Citations 10

Authors

J J Wamsley

C Gary

A Biktasova

M Hajek

G Bellinger

R Virk

N Issaeva

W G Yarbrough

Affiliations

Soon will be listed here.

Abstract

Chemotherapy and radiation, the two most common cancer therapies, exert their anticancer effects by causing damage to cellular DNA. However, systemic treatment damages DNA not only in cancer, but also in healthy cells, resulting in the progression of serious side effects and limiting efficacy of the treatment. Interestingly, in response to DNA damage, p53 seems to play an opposite role in normal and in the majority of cancer cells-wild-type p53 mediates apoptosis in healthy tissues, attributing to the side effects, whereas mutant p53 often is responsible for acquired cancer resistance to the treatment. Here, we show that leucine zipper-containing ARF-binding protein (LZAP) binds and stabilizes p53. LZAP depletion eliminates p53 protein independently of its mutation status, subsequently protecting wild-type p53 cells from DNA damage-induced cell death, while rendering cells expressing mutant p53 more sensitive to the treatment. In human non-small-cell lung cancer, LZAP levels correlated with p53 levels, suggesting that loss of LZAP may represent a novel mechanism of p53 inactivation in human cancer. Our studies establish LZAP as a p53 regulator and p53-dependent determinative of cell fate in response to DNA damaging treatment.

Citing Articles

Multifaceted roles of UFMylation in health and disease.

Wang R, Li L, Zhou J, Ran J Acta Pharmacol Sin. 2025; .

PMID: 39775503 DOI: 10.1038/s41401-024-01456-9.

Porcine alveolar macrophages host proteins interacting with African swine fever virus p72.

Weng Z, Zheng X, Liang Y, Chen X, Peng Q, Zhang G Front Microbiol. 2024; 15:1370417.

PMID: 38481793 PMC: 10932996. DOI: 10.3389/fmicb.2024.1370417.

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.

Shen J, Wang Q, Mao Y, Gao W, Duan S MedComm (2020). 2023; 4(3):e288.

PMID: 37256211 PMC: 10225743. DOI: 10.1002/mco2.288.

Cyclin-Dependent Kinase 5 Regulatory Subunit Associated Protein 3: Potential Functions and Implications for Development and Disease.

Sheng L, Li J, Rao S, Yang Z, Huang Y Front Oncol. 2021; 11:760429.

PMID: 34722315 PMC: 8551632. DOI: 10.3389/fonc.2021.760429.

CDK5RAP3, a Novel Nucleoplasmic Shuttle, Deeply Regulates HSF1-Mediated Heat Stress Response and Protects Mammary Epithelial Cells from Heat Injury.

Shen Y, Zou Y, Li J, Chen F, Li H, Cai Y Int J Mol Sci. 2020; 21(21).

PMID: 33182370 PMC: 7664939. DOI: 10.3390/ijms21218400.

References

Bargonetti J, Manfredi J . Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002; 14(1):86-91. DOI: 10.1097/00001622-200201000-00015. View

Phan R, Dalla-Favera R . The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004; 432(7017):635-9. DOI: 10.1038/nature03147. View

El-Deiry W . Regulation of p53 downstream genes. Semin Cancer Biol. 1999; 8(5):345-57. DOI: 10.1006/scbi.1998.0097. View

Kim M, Sgagias M, Deng X, Jung Y, Rikiyama T, Lee K . Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression. Biochem Biophys Res Commun. 2004; 320(1):138-44. DOI: 10.1016/j.bbrc.2004.05.135. View

Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman K, Farnebo M . Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009; 33(4):462-71. DOI: 10.1016/j.molcel.2009.01.028. View

Oren M, Rotter V . Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2(2):a001107. PMC: 2828285. DOI: 10.1101/cshperspect.a001107. View

Lee M, Teoh W, Phang B, Tong W, Wang Z, Sabapathy K . Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell. 2012; 22(6):751-64. DOI: 10.1016/j.ccr.2012.10.022. View

Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P . Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2010; 18(1):2-11. DOI: 10.1038/cgt.2010.63. View

Momand J, Jung D, Wilczynski S, Niland J . The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26(15):3453-9. PMC: 147746. DOI: 10.1093/nar/26.15.3453. View

10.

Jiang H, Luo S, Li H . Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J Biol Chem. 2005; 280(21):20651-9. DOI: 10.1074/jbc.M413431200. View

11.

Maier P, Wenz F, Herskind C . Radioprotection of normal tissue cells. Strahlenther Onkol. 2014; 190(8):745-52. DOI: 10.1007/s00066-014-0637-x. View

12.

Goloudina A, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin D . Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A. 2011; 109(2):E68-75. PMC: 3258624. DOI: 10.1073/pnas.1107017108. View

13.

Mayo L, Donner D . The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27(9):462-7. DOI: 10.1016/s0968-0004(02)02166-7. View

14.

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

15.

Hupp T, Lane D, Ball K . Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J. 2000; 352 Pt 1:1-17. PMC: 1221427. View

16.

Wamsley J, Issaeva N, An H, Lu X, Donehower L, Yarbrough W . LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro. Cell Cycle. 2016; 16(2):213-223. PMC: 5283812. DOI: 10.1080/15384101.2016.1261767. View

17.

Gary C, Hajek M, Biktasova A, Bellinger G, Yarbrough W, Issaeva N . Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016; 7(25):38598-38611. PMC: 5122414. DOI: 10.18632/oncotarget.9560. View

18.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

19.

Mayo L, Dixon J, Durden D, Tonks N, Donner D . PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2001; 277(7):5484-9. DOI: 10.1074/jbc.M108302200. View

20.

Lynch C, Milner J . Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene. 2006; 25(24):3463-70. DOI: 10.1038/sj.onc.1209387. View